247 assets in Acute Lymphoblastic Leukemia

Therapeutic assets addressing Acute Lymphoblastic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Levofolinic Acid Acute Lymphoblastic Leukemia	Children's Oncology Group	P3	CCC (52)
lp-118 Acute Lymphoblastic Leukemia	University of Chicago	P1/2	CCC (52)
Pcar-19B Cells Acute Lymphoblastic Leukemia	Chongqing Precision Biotech Co., Ltd	P2	CCC (52)
Ruxolitinib Phosphate Acute Lymphoblastic Leukemia	City of Hope Medical Center	P2	CCC (52)
Zoledronate Acute Lymphoblastic Leukemia	Children's Hospital of Eastern Ontario	P2	CCC (52)
Flumatinib Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Levetiracetam Acute Lymphoblastic Leukemia	Center for International Blood and Marrow Transplant Research	P2	CCC (51)
Palifermin Acute Lymphoblastic Leukemia	Center for International Blood and Marrow Transplant Research	P2	CCC (51)
Siltuximab Acute Lymphoblastic Leukemia	University of Alabama at Birmingham	P2	CCC (51)
Baricitinib Acute Lymphoblastic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2/3	CCC (50)
Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-Hydroxy-4-Methylpentyl)Butanedioate (Ester) Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2/3	CCC (50)
Letermovir Acute Lymphoblastic Leukemia	City of Hope Medical Center	P2	CCC (50)
Trametinib Acute Lymphoblastic Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CCC (50)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Apamistamab-B10-Astatine At-211 Acute Lymphoblastic Leukemia	Fred Hutchinson Cancer Center	P1/2	CCC (48)
Axicabtagene Ciloleucel Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals	P2	CCC (48)
Beam-201 Acute Lymphoblastic Leukemia	Beam Therapeutics Inc.	P1/2	CCC (48)
Bebt 908 Acute Lymphoblastic Leukemia	Ruijin Hospital	P2	CCC (48)
Brexucabtagene Autoleucel Acute Lymphoblastic Leukemia	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
Breyanzi Injectable Product Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Calaspargase Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P2	CCC (48)
Enzomenib Acute Lymphoblastic Leukemia	Sumitomo Pharma America, Inc.	P1/2	CCC (48)
Epirubicin Acute Lymphoblastic Leukemia	National Hospital Organization Nagoya Medical Center	P2	CCC (48)
Gilteritinib Acute Lymphoblastic Leukemia	Sumitomo Pharma America, Inc.	P1/2	CCC (48)
Human Culture Expanded Genetically Modified Autologous T Cells For Cell-Based Gene Therapy. Cells Are Derived From Isolated Blood Of The Patient And Are Transduced With Non-Replicative Self-Inactivating (Sin) Human Immunodeficiency Virus Type 1 (Hiv-1) Based Lentiviral Vector (Lvv) Pseudotyped With The Vesicular Stomatitis Virus Glycoprotein G (Vsv-G) Envelope Protein, And Encoding The C11D5.3 Anti-Tnf Receptor Superfamily Member 17 (Tnfrsf17, Bcma) Single Chain Variable Fragment (Scfv) Cd8/4-1Bb/Cd3Zeta Chimeric Antigen Receptor (Car) Under The Transcriptional Control Of The Myeloproliferative Sarcoma Virus Enhancer, Negative Control Region Deleted, Dl587Rev Primer-Binding Site Substituted (Mnd) Promote Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Inaticabtagene Autoleucel Acute Lymphoblastic Leukemia	First Affiliated Hospital of Zhejiang University	P2	CCC (48)
Navitoclax Acute Lymphoblastic Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CCC (48)
NK-92 Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	P2	CCC (48)
Obecabtagene Autoleucel Chimeric Antigen Receptor Acute Lymphoblastic Leukemia	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Orca-Q Acute Lymphoblastic Leukemia	University of Florida	P1/2	CCC (48)
Pbsc Acute Lymphoblastic Leukemia	Fred Hutchinson Cancer Center	P2	CCC (48)
Ptg-Carcik-Cd19 Acute Lymphoblastic Leukemia	Fondazione Matilde Tettamanti Menotti De Marchi Onlus	P2	CCC (48)
Rabbit Anti-Human Thymocyte Globulin Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (48)
Retinol Acute Lymphoblastic Leukemia	St. Petersburg State Pavlov Medical University	P2	CCC (48)
sar443579 Acute Lymphoblastic Leukemia	Sanofi	P1/2	CCC (48)
Sc-Peg Acute Lymphoblastic Leukemia	Dana-Farber Cancer Institute	P2	CCC (48)
Shb-02-Cd19 Acute Lymphoblastic Leukemia	Sheba Medical Center	P1/2	CCC (48)
shr2554 Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (48)
Tirzepatide Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P2	CCC (48)
car19tif cells Acute Lymphoblastic Leukemia	Chinese PLA General Hospital	P1/2	CC (47)
Ipilimumab Acute Lymphoblastic Leukemia	OHSU Knight Cancer Institute	P1	CC (47)
Itacitinib Acute Lymphoblastic Leukemia	City of Hope Medical Center	P2	CC (47)
pd5k3 Acute Lymphoblastic Leukemia	Chongqing Peg-Bio Biopharm Co., Ltd.	P1	CC (47)
Selinexor Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P1	CC (47)
Tcr Reserved And Power3 (Sppl3) Gene Knock-Out Allogeneic Cd19-Targeting Car-T Cell Acute Lymphoblastic Leukemia	Chinese PLA General Hospital	P1/2	CC (47)
kt-253 Acute Lymphoblastic Leukemia	Kymera Therapeutics, Inc.	P1	CC (46)
Recombinant Human Granulocyte Colony-Stimulating Factor Acute Lymphoblastic Leukemia	City of Hope Medical Center	P1/2	CC (46)
Autologous Cd7 Car T-Cell Acute Lymphoblastic Leukemia	Beijing GoBroad Hospital	P1/2	CC (45)
cd19- specific car engineered autologous t-cells Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P1/2	CC (45)
Dilanubicel Acute Lymphoblastic Leukemia	Fred Hutchinson Cancer Center	P2	CC (45)

Showing 101 to 150 of 247 assets

PreviousPage 3 of 5Next